GLP-1 Pathway drugs (Incretin Therapy) for Diabetes Melitus: Physiology, Clinical Rationale and Implications for the Exocrine Pancreas

被引：0
|
作者：
Fine, David
机构：
来源：
PANCREATOLOGY | 2016年 / 16卷 / 01期
关键词：
D O I：
10.1016/j.pan.2016.01.008
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1 / 1
页数：1
相关论文
共 30 条
  • [21] The effectiveness of SGLT-2 inhibitors as second-line treatments for NAFLD patients with type 2 diabetes mellitus who failed to incretin based therapy including GLP-1 analogues and DPP-4 inhibitors
    Ohki, Takamasa
    Akihiro, Isogawa
    Toda, Nobuo
    HEPATOLOGY, 2015, 62 : 1299A - 1299A
  • [22] Real-world clinical outcomes following treatment intensification with GLP-1 RA, OADs or insulin in patients with type 2 diabetes on two oral agents (PATHWAY 2-OADs)
    Desouza, Cyrus
    Kirk, Andreas R.
    Mangla, Kamal K.
    Wolden, Michael L.
    Lingvay, Ildiko
    BMJ OPEN DIABETES RESEARCH & CARE, 2020, 8 (02)
  • [23] The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial
    Sultan Linjawi
    Bruce W. Bode
    Louis B. Chaykin
    Jean-Pierre Courrèges
    Yehuda Handelsman
    Lucine M. Lehmann
    Abhishek Mishra
    Richard W. Simpson
    Diabetes Therapy, 2017, 8 : 101 - 114
  • [24] The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial
    Linjawi, Sultan
    Bode, Bruce W.
    Chaykin, Louis B.
    Courreges, Jean-Pierre
    Handelsman, Yehuda
    Lehmann, Lucine M.
    Mishra, Abhishek
    Simpson, Richard W.
    DIABETES THERAPY, 2017, 8 (01) : 101 - 114
  • [25] SGLT2 Inhibitor and GLP-1 Receptor Agonist Combination Therapy Substantially Improved the Renal Function in a Patient with Type 2 Diabetes: Implications for Additive Renoprotective Effects of the Two Drug Classes
    Nonomura, Kenta
    Iizuka, Katsumi
    Kuwabara-Ohmura, Yayoi
    Yabe, Daisuke
    INTERNAL MEDICINE, 2020, 59 (12) : 1535 - 1539
  • [26] Clinical Utility of Cardiovascular Risk Scores for Identification of People With Type 2 Diabetes More Likely to Benefit From Either GLP-1 Receptor Agonist or SGLT2 Inhibitor Therapy
    Sacre, Julian W.
    Magliano, Dianna J.
    Shaw, Jonathan E.
    DIABETES CARE, 2022, 45 (08) : 1900 - 1906
  • [27] Precision medicine in type 2 diabetes: Simple clinical characteristics alter the glucose-lowering efficacy of SGLT2-inhibitors and GLP-1 receptor agonists and can determine optimal therapy choice
    Cardoso, P.
    Young, K. G.
    Hopkins, R.
    Raya, D.
    Jones, A. G.
    Pearson, E. R.
    Hattersley, A. T.
    Shields, B. M.
    McKinley, T. J.
    Dennis, J. M.
    DIABETIC MEDICINE, 2023, 40
  • [28] Clinical Characteristics of Patients With Uncontrolled Type 2 Diabetes (T2DM) on One or Two Oral Agents According to Intensification of Therapy With Insulin, Glucagon-Like Peptide 1 Agonists (GLP-1), or Additional Oral Anti-Diabetes Agents (OAD)
    Magaji, Vasudev
    Lombardero, Manuel
    Siminerio, Linda M.
    Saul, Melissa
    Brooks, Maria
    Orchard, Trevor J.
    Korytkowski, Mary T.
    DIABETES, 2012, 61 : A616 - A616
  • [29] Cardiac resynchronization therapy with a defibrillator (CRTd) in failing heart patients with type 2 diabetes mellitus and treated by glucagon-like peptide 1 receptor agonists (GLP-1 RA) therapy vs. conventional hypoglycemic drugs: arrhythmic burden, hospitalizations for heart failure, and CRTd responders rate
    Sardu, Celestino
    Paolisso, Pasquale
    Sacra, Cosimo
    Santamaria, Matteo
    de Lucia, Claudio
    Ruocco, Antonio
    Mauro, Ciro
    Paolisso, Giuseppe
    Rizzo, Maria Rosaria
    Barbieri, Michelangela
    Marfella, Raffaele
    CARDIOVASCULAR DIABETOLOGY, 2018, 17
  • [30] Cardiac resynchronization therapy with a defibrillator (CRTd) in failing heart patients with type 2 diabetes mellitus and treated by glucagon-like peptide 1 receptor agonists (GLP-1 RA) therapy vs. conventional hypoglycemic drugs: arrhythmic burden, hospitalizations for heart failure, and CRTd responders rate
    Celestino Sardu
    Pasquale Paolisso
    Cosimo Sacra
    Matteo Santamaria
    Claudio de Lucia
    Antonio Ruocco
    Ciro Mauro
    Giuseppe Paolisso
    Maria Rosaria Rizzo
    Michelangela Barbieri
    Raffaele Marfella
    Cardiovascular Diabetology, 17
123